Procode Raises $10M in Series A Funding

Procode Inc. has raised a $10M Series A led by Health Velocity Capital. The Los Angeles company plans to use the financing to acquire two additional medical billing businesses, expand into more surgical specialties, and strengthen its presence in ambulatory surgical center billing.

The round brings Procode's company-reported total venture funding to $14M. It also gives the company an opportunity to prove a sharper healthcare AI thesis: acquire specialty billing operations with established workflow expertise, then apply domain-specific coding and revenue-cycle technology where success can be measured through collections, denials, and operating margins.

That distinction matters because private-practice billing is not a clean software problem waiting for a better interface. It is a dense operating system of payer rules, procedure codes, documentation requirements, follow-up work, and specialty knowledge, with revenue left behind whenever any part of that chain breaks.

What Happened

Procode announced the Series A on July 28, 2026, with Health Velocity Capital leading the round. An SEC Form D filed earlier in the month listed a total offering of $9,999,989 and $9,499,996 sold at that stage, explaining why some financing databases initially reported the transaction as $9.5M before the company announced the completed $10M raise.

The capital will fund a buy-and-build strategy. Procode says it will acquire two additional medical billing companies, apply its AI coding and revenue-cycle technology, and expand beyond its current focus on plastic surgery and dermatology into additional surgical specialties and ambulatory surgical centers.

The company has already followed this playbook once. Procode launched publicly in March 2026 with $4M in prior financing and the acquisition of The Auctus Group, a specialty medical billing business serving plastic surgery and dermatology practices. Procode now says that operation supports more than 350 providers.

Why This Matters

Many AI funding announcements focus on whether a model is technically impressive. Procode's financing asks a different question: can software become materially better by acquiring the operating context it needs instead of waiting for customers to provide clean data, standardized processes, and flawless implementation?

Specialty billing companies already possess practical knowledge that general-purpose software often lacks. They understand where documentation fails, which claims require human attention, how payer behavior varies by procedure, and why a denial that appears routine on a dashboard can become expensive after weeks in accounts receivable. Procode's strategy is to preserve that expertise while introducing automation across coding, collections, reporting, and provider visibility.

The company's platform reflects that operating philosophy. Procode manages surgical coding from charge capture through claim submission, Procollect supports billing-team reporting and workflow automation, and the Auctus Provider App gives clients real-time financial and claims visibility. Together, those products are designed to function as a unified revenue-cycle platform rather than another AI assistant sitting alongside existing workflows.

Procode says it is on track to double The Auctus Group's revenue and increase its EBITDA margin fivefold. Those figures are company-reported targets rather than audited results, but they illustrate what investors are underwriting: not simply faster task execution, but an operating model in which software, services, and acquisitions reinforce one another.

The Technical Evidence

Procode's technical story gained stronger validation in July. A peer-reviewed retrospective study published in Plastic and Reconstructive Surgery Global Open evaluated exact CPT code-set accuracy across 120 operative reports, divided evenly into low-, medium-, and high-complexity cases.

The study reported that Procode's fine-tuned hybrid system achieved 100% accuracy on low-complexity reports and 80% accuracy on both medium- and high-complexity reports. Procode's funding announcement also reported 86.7% overall accuracy, compared with 42.5% for external professional auditors and 35.8% for the highest-performing general-purpose model included in the evaluation.

The findings are encouraging, but they do not represent a universal validation of automated medical coding. Several study authors were affiliated with Procode and participated in developing the system, while the dataset focused exclusively on plastic and reconstructive surgery. The research strengthens the case for domain-specific coding systems in complex clinical environments while leaving open the more difficult question of how those results will translate across specialties, payer environments, and live production workflows.

Market Context

Revenue cycle management occupies a difficult position within healthcare technology. It is essential, highly procedural, and closely tied to cash flow, making every improvement in coding accuracy financially meaningful. At the same time, it remains fragmented across specialty firms, legacy workflows, and systems that were never designed to operate as a unified platform.

Large health systems can invest in specialized software, internal teams, and lengthy implementation cycles. Smaller practices and independent billing companies face many of the same coding and reimbursement challenges with fewer resources, creating an opportunity for a company that combines software economics with service delivery and specialty expertise.

Health Velocity Capital's lead investment reflects that thesis. The firm focuses on healthcare software and services, and partner Grant Blevins described Procode as a way to give smaller billing-business owners an AI strategy while preserving the expertise that made those businesses valuable. That investment case is more grounded than simply attaching a chatbot to a legacy workflow and hoping reimbursement improves.

What This Signals

Procode's Series A suggests healthcare AI may advance through acquisition as much as product-led adoption. Buying specialty billing businesses gives the company customer relationships, operating data, domain expertise, and direct visibility into the financial outcomes its software is designed to improve.

The strategy also introduces meaningful execution risk. Procode must integrate multiple businesses, retain specialty expertise, maintain billing accuracy, and demonstrate that a system validated in one surgical specialty can expand into others without losing precision. Acquisitions can accelerate distribution, but they can also create a collection of processes that resist standardization.

For operators and investors, the next proof point is not another benchmark. It is whether Procode can repeat the Auctus integration, deliver measurable improvements in collections and operating margins, and expand successfully into new specialties while keeping experienced specialists close to the work.

The $10M Series A gives the company room to pursue that objective. If Procode succeeds, its advantage will not come from AI alone. It will come from combining domain-specific technology, acquired operating expertise, and a business model tied directly to whether healthcare providers get paid.